JP2007535471A5 - - Google Patents

Download PDF

Info

Publication number
JP2007535471A5
JP2007535471A5 JP2006509122A JP2006509122A JP2007535471A5 JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5 JP 2006509122 A JP2006509122 A JP 2006509122A JP 2006509122 A JP2006509122 A JP 2006509122A JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5
Authority
JP
Japan
Prior art keywords
antibody
binds
library
cll
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535471A (ja
Filing date
Publication date
Priority claimed from US10/379,151 external-priority patent/US7435412B2/en
Priority claimed from US10/736,188 external-priority patent/US20040198661A1/en
Application filed filed Critical
Publication of JP2007535471A publication Critical patent/JP2007535471A/ja
Publication of JP2007535471A5 publication Critical patent/JP2007535471A5/ja
Pending legal-status Critical Current

Links

JP2006509122A 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用 Pending JP2007535471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/379,151 US7435412B2 (en) 2000-12-08 2003-03-04 Chronic lymphocytic leukemia cell line
US10/379,151 2003-03-04
US10/736,188 2003-12-15
US10/736,188 US20040198661A1 (en) 2000-12-08 2003-12-15 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PCT/US2004/006577 WO2004078938A2 (en) 2003-03-04 2004-03-04 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2007535471A JP2007535471A (ja) 2007-12-06
JP2007535471A5 true JP2007535471A5 (https=) 2008-01-24

Family

ID=32965320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509122A Pending JP2007535471A (ja) 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用

Country Status (6)

Country Link
US (1) US20040198661A1 (https=)
EP (1) EP1606388A4 (https=)
JP (1) JP2007535471A (https=)
KR (1) KR20050108381A (https=)
CA (1) CA2517968A1 (https=)
WO (1) WO2004078938A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7427665B2 (en) * 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
HUE028179T2 (en) 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2009014744A1 (en) * 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Methods and compositions for treating autoimmune disease
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CA2744400C (en) * 2008-11-25 2019-01-15 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2477658A2 (en) * 2009-09-16 2012-07-25 Duke University Hiv-1 antibodies
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CA2786692A1 (en) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) * 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2405246A1 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5508717A (en) * 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US7291330B2 (en) * 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
CA2429579A1 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7427665B2 (en) * 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200

Similar Documents

Publication Publication Date Title
JP2007535471A5 (https=)
RU2582265C2 (ru) АНТИТЕЛО ПРОТИВ cMet И ЕГО ПРИМЕНЕНИЕ ДЛЯ ОПРЕДЕЛЕНИЯ И ДИАГНОСТИКИ РАКА
JP2019116474A5 (https=)
JP4280803B2 (ja) 慢性リンパ性白血病細胞株および抗体を産生するためのその使用
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
JP2009517057A5 (https=)
JP2020522513A5 (https=)
JP2013506428A5 (https=)
JP2012176953A5 (https=)
JP2021520208A5 (https=)
JP7245358B2 (ja) 抗ｃｄ２５抗体及びその適用
WO2006020266A2 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
NZ601858A (en) Methods and compositions for diagnosis and treatment of amyloidosis
JP2021517152A5 (https=)
JP2019512207A5 (https=)
JP2009509538A5 (https=)
EP2736926A1 (en) Use of the antibody i-3859 for the detection and diagnosis of cancer
EP3397965A1 (en) Compositions and methods for assessing the risk of cancer occurrence
US12091457B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
JPWO2019175885A5 (https=)
JP2020515286A5 (https=)
US20240117042A1 (en) Immunohistochemistry methods and kir3dl2-specific reagents
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
JP2021516989A5 (https=)
JP7821779B2 (ja) 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出